GT Biopharma Balance Sheet Health
Financial Health criteria checks 6/6
GT Biopharma has a total shareholder equity of $7.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $14.1M and $6.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$13.97m |
| Equity | US$7.48m |
| Total liabilities | US$6.63m |
| Total assets | US$14.11m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: OXIA's short term assets ($14.1M) exceed its short term liabilities ($6.6M).
Long Term Liabilities: OXIA has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: OXIA is debt free.
Reducing Debt: OXIA has no debt compared to 5 years ago when its debt to equity ratio was 95%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OXIA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: OXIA has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 12.1% each year.